This appraisal is intended for use by advanced practice nurses and emergency nurse clinicians who are involved in the assessment and management of Group A streptococcal pharyngitis in the emergency department and urgent care centers and for health care administrators who are involved in the allocation of resources for corresponding testing and antimicrobial dispensing 
departments (EDs) and urgent care centers, and the decision to prescribe antibiotics upon symptom presentation continues to be a challenge for health care providers at a time when antimicrobial resistance is of great global concern (Laxminarayan et al., 2013) . Unnecessary antibiotic prescribing for sore throats has been documented nationwide, with 54% of nurse practitioners and 65% of physicians prescribing antibiotics for nonstreptococcal pharyngitis (Ladd, 2005) . This article critically appraises the latest guideline by the Infectious Diseases Society of America (IDSA) for the diagnosis and management of Group A streptococcal (GAS) pharyngitis. It is imperative that advanced practice registered nurses (APRNs) understand and apply this guideline in treating pharyngitis to avoid deleterious effects of unnecessary antibiotic prescribing.
Clinical practice guidelines should provide recommendations for practicing clinicians using the best available evidence. It is important for APRNs to effectively evaluate guidelines for quality of evidence and the possibility of bias prior to guideline adoption. The Appraisal Guideline for Research and Evaluation (AGREE) tool is an instrument with proven validity and clinical applicability that is commonly used to evaluate research-based guidelines (Brouwers et al., 2010a (Brouwers et al., , 2010b . The tool contains systematically developed statements formulated into 23 questions that enable reviewers and practitioners to make decisions regarding evidence-based health practices and concordant health policy changes. Originally developed in Canada, the AGREE tool assesses transparency, methodological strategies, and applicability in a scoring system based on six evaluation domains: scope and purpose; stakeholder involvement; rigor of development; clarity of presentation; applicability; and editorial independence (Brouwers et al., 2010a (Brouwers et al., , 2010b .
The tool was provided to four professionals who were asked to independently critique and rate the "Clinical Practice Guideline for the Diagnosis and Management of GAS Pharyngitis: 2012 Update by the IDSA" published in this organization's Clinical Infectious Diseases journal (Shulman et al., 2012) . The results of the group findings are presented and discussed.
METHODS
The Version II AGREE tool includes recent improvements in the accuracy of the measurements among all domain variables. Validity testing of the AGREE tool (Brouwers et al., 2010a (Brouwers et al., , 2010b revealed that it successfully differentiates between high-and lowquality guidelines (p < 0.05). In the current analysis, three master's prepared APRNs and one doctorally prepared APRN used the Version II AGREE tool to independently appraise the "Clinical Practice Guideline for the Diagnosis and Management of GAS Pharyngitis: 2012 Update by the IDSA". Each professional independently scored each element of the six domains (scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, and editorial independence) on a scale of 1-7. Reviewers provided comments to justify their scores. The AGREE tool does not permit zero scores or element score omission, nor does it calculate an overall interrater score for the entire guideline. The percentage scores for each domain were calculated on the basis of the formula incorporated in the AGREE tool. The quantifiable results are listed in Table 1 , and critical comments for each domain are described in the body of this document.
Scope and Purpose
The purpose of the clinical practice guideline was clearly stated as the provision of recommendations for the diagnosis and management of GAS pharyngitis. The recommendations can help guide clinicians in recognizing patients who should or should not be tested with the rapid antigen detection test (RADT), by identifying age group risk categories for follow-up throat cultures, and by listing symptom likelihood of bacterial versus viral etiology. It also made distinctions for Strep carriers, children younger than 3 years, adolescents, and adults, and made recommendations for antimicrobial selection and adjunctive therapies. The guideline strongly discourages unnecessary antimicrobials and provides evidence-based rationales for all recommendations.
Stakeholder Involvement
The IDSA guideline panel convened in 2009 with a face-to-face meeting, followed by individual assignments and multiple teleconferences, to update the 2002 recommendations. The panel consisted of eight multidisciplinary experts, mostly infectious disease physicians, pediatricians, and physicians from the Centers for Disease Control and 3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described. 7 100% Domain 2: Stakeholder involvement 4. The guideline development group includes individuals from all relevant professional groups.
6.5
5. The patients' views and preferences have been sought. 1.5 6. The target users of the guideline are clearly defined. 7 67% Domain 3: Rigor of development 7. Systematic methods were used to search for evidence. 6.5 8. The criteria for selecting the evidence are clearly described.
5.8 9. The strengths and limitations of the body of evidence are clearly described.
6.2 10. The methods for formulating the recommendations are clearly described.
6
11. The health benefits, side effects, and risks have been considered in formulating the recommendations.
12. There is an explicit link between the recommendations and the supporting evidence.
6.2
13. The guideline has been externally reviewed by experts prior to its publication. Note: Each item is rated on a 7-point scale from 1 ("strongly disagree") to 7 ("strongly agree"), with a midpoint of 4 denoting neutrality of "neither agree nor disagree." The scale measures the extent to which each component item contributes to the evaluated domain score.
Prevention, Respiratory Diseases Branch, with members belonging to hospital organizations from across the nation. Although the target users (clinicians involved in the diagnosis and management of GAS pharyngitis) of the guideline were clearly identified, the panel did not include epidemiologists, microbiologists, infectious disease nurses, pharmacists, school nurses, or APRNs. The guideline was authoritative in its presentation and did not take into account patient preferences in the formulation of the guideline. In the event of a community outbreak of GAS pharyngitis, the guideline considered patient anxiety but recommended clinical evaluation only for symptomatic patients.
Rigor of Development
The panel gathered evidence from 1980 to 2012 from systematic reviews found in major search engines. Where no systematic reviews were available, original studies were used. In some instances, meta-analyses were used (e.g., to estimate a higher incidence of GAS pharyngitis in school-aged children) but it largely entailed systematic reviews of randomized controlled trials. No other selection inclusion or exclusion criteria aside from the search words were provided. Because the studies selected were limited to the English language, international guidelines and Level I evidence on the management of antimicrobials for pharyngitis from other countries may have been omitted. The peer-review reliability was established by the use of an expert panel consisting of the IDSA guideline committee and board members and two key physicians with experience in guideline development. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria (Balshem, et al., 2011) to formulate recommendations based on structured criteria that entail the quality of the evidence, the desirable outcome versus undesirable effects, and the likelihood of change should further research findings become available. The IDSA guideline recommendations discussed in this document were based on multiple sources of evidence, and an effort was made to link evidence to the incidence of GAS pharyngitis, diagnostic modalities, associated risks of complications, and decisions regarding antimicrobial treatment. The guideline stressed recognition of the actual incidence of streptococcus pharyngitis in various populations in an effort to link the evidence to antibiotic prescribing. For example, only 5-15% of adult sore throat visits (Ebell, Smith, Barry, Ives, & Carey, 2000) , 37% of symptomatic pediatric visits (24% in children younger than 5 years), and 12% in asymptomatic children (Shaik & Martin, 2010) . In addition, the incidence of rheumatic fever is extremely low among adults in developed countries where the natural course of Strep pharyngitis is self-limited to less than 7 days (Spinks, Glasziou, & Del Mar, 2013) . However, antibiotic prescribing among adults and pediatric patients commonly far exceeds these rates. The guideline summarizes recommendations, with consistently strong direction of results across multiple studies.
The guideline presents the following recommendations using the GRADE criteria:
1. The diagnosis of GAS pharyngitis is to be made by RADT and/or culture testing in children older than 3 years. Guideline limitations include a failure to address the international controversy over the use of diagnostic tools and clinical scoring systems (e.g., McIsaac's 4-point diagnostic criteria for GAS; McIsaac, Goel, To, & Low, 2000) . Also included in this domain is a requirement for full disclosure of possible conflict of interest. It was revealed that two members had previous consulting functions with vaccine and pharmaceutical companies and had received research funding. Financial funding for the guideline itself was provided by the IDSA. The authors intend for the guideline to be reviewed yearly by guideline committee board members, and, if necessary, the entire panel will be reconvened to denote changes. In 2014, Shulman et al. released a guideline correction regarding azithromycin dosage recommendations for patients allergic to penicillin. The newly recommended dose is 12 mg/kg once (maximum of 500 mg), followed by 6 mg/kg (maximum 250 mg) daily for 4 days. Narrowspectrum cephalosporin (provided there is no history of anaphylactic-like hypersensitivity to penicillin), clindamycin, and macrolide (e.g., clarithromycin) antibiotic alternatives continue to be recommended. It is worth noting that certain macrolides (namely, erythromycin) have been discouraged in other guidelines because of antimicrobial resistance (Chiappini et al., 2011) .
Clarity of Presentation
The guideline presents clear directives and evidence summaries that answer pertinent questions regarding the diagnosis and management of Strep pharyngitis. It provides a table for distinguishing common symptoms for viral and bacterial pharyngitis and various antimicrobial treatments. It presents prior research regarding the use of clinical scores to diagnose Strep pharyngitis but states that because of so many overlapping symptoms, the scoring system, if used alone, can actually encourage a higher rate of antibiotic prescribing than the actual rate of Strep pharyngitis existence. This is congruent with other studies that show a three to four times likelihood of unnecessary prescribing when Copyright © 2015 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. scoring systems are used alone (McIsaac, Kellner, Aufricht, Vanjaka, & Low, 2004) . What is not sufficiently stated by the guideline authors is that the scoring modalities can actually assist in screening patients for RADT. Although the authors discourage the use of algorithms because they state that it leads to overprescribing for GAS pharyngitis, an algorithm could have been helpful to illustrate the guideline recommendations. A sample of a clinical decision algorithm is depicted in Figure 1 .
Applicability
The guideline provides clear recommendations and practical considerations for RADT based on cost of test versus treatment, and the cost of certifying staff to run this CLIA (Clinical Laboratory Improvement Amendment) waved bedside test. The cost of such implementation overall would be much less than the $539 million Strep pharyngitis treatment costs in the Unites States every year (Pfoh, Wessels, Goldman, & Lee, 2008) . The guideline is available on the IDSA website, but the website does not include any additional training, algorithms, or practical tools for providers. The guideline stresses the importance of not prescribing antibiotics for nonstreptococcal pharyngitis, but it does not commit to numerical criteria congruent with the documented existence of Strep pharyngitis in children and adults, which could be used to monitor progress of antibiotic prescribing. For example, if the incidence of Strep pharyngitis is 24%-37% in pediatric patients presenting with pharyngitis, and in only 5%-15% of adults, then antimicrobial prescribing should not exceed their corresponding incidence rates. If this guideline is implemented, the selection for diagnostic testing and treatment should ideally approximate the frequency of the existence of GAS pharyngitis in the corresponding population. A challenge is that patients or guardians may be unwilling to accept the lack of diagnostic testing for their viral-like symptoms that do not warrant the RADT. An additional consideration is the severity of the patient clinical presentation and comorbidities such as preexisting cardiac disease or immune compromise, which are not mentioned in the guideline Figure 1 . Algorithm for testing and prescribing for pharyngitis. Decision tree based on clinical presentation, testing results, and likelihood of Group A streptococcal pharyngitis per age group risk categories. Adult population is considered low risk for rheumatic fever for which no routine backup streptococcal cultures or antibiotic prophylaxis is indicated. Guideline reflective of this algorithm does not replace individual patient considerations, including severity of symptoms. RADT = rapid antigen detection test (forand which would increase the likelihood of appropriate antibiotic prescribing. Still, the guide can be applied to multiple outpatient settings, including EDs, clinics, private offices, and community settings. Emergency nurses practitioners can use these guidelines both in assessing patient/family risk and in providing patient education and guidance. Emergency department and outpatient clinic administrators should recognize that RADT is a good use of resources in differentiating cases of non-Strep pharyngitis. RADT reduces the cost of unnecessary antibiotic prescription and throat culture testing in adults who have a low incidence of acute Strep pharyngitis. It is also in the best financial interest of health care insurance providers to reimburse medical facilities for running the test.
Editorial Independence
Funding was provided by the guideline parent organization. There appeared to be no significant interest in antimicrobial prescribing, as it was generally discouraged, or for ordering tests, as they were discouraged in the vast majority of cases of sore throats due to their viral etiology. Also, the use of newer well-advertised broad-spectrum antibiotics was discouraged. Adherence to the guideline is voluntary, with provider discretion to be applied toward the use of initial or backup cultures according to individual patient findings and provider preference for increased accuracy of diagnosis.
AGREE SCORE SUMMARY RESULTS
The "Clinical Practice Guideline for the Management of GAS Pharyngitis: 2012 Update by the IDSA" was individually appraised by four APRNs using the AGREE tool. Scores ranged from 1 to 7 for each of six domain elements, and percentage domain scores are listed in Table 1 . The guideline strengths were scope and purpose (100%) and clarity of presentation (97%). The guidelines scored 85% on rigor of development and 85% on editorial independence. Stakeholder involvement scored only 67% because of limited seeking of patient views and preferences, which are important for APRNs in the application of research findings. Applicability scored 59% because of the omission of barriers and facilitators to its application, but other elements contained in the applicability domain (such as recommendations and resource implications for practice) scored fairly well.
DISCUSSION
Overall, the guideline answers key clinical questions regarding the diagnosis and management of GAS pharyngitis. The guideline's usability would benefit from an illustrated algorithm, and an algorithm was subsequently developed by the study group (see Figure 1 ). Advanced practice emergency nurses can use the "Clinical Practice Guideline for the Diagnosis and Treatment of GAS Pharyngitis: 2012 Update of the IDSA" to make decisions about diagnostic testing and antibiotic treatment. This will ultimately result in a decrease in unnecessary antibiotic prescribing and antimicrobial resistance. Attempts should be made to match the rate of prescribing to the actual rate of GAS pharyngitis in the population.
